Sun Pharma Vs Dr Reddy’s Lab Vs Granules India Vs Mankind Pharma: Amid ongoing geopolitical uncertainty, the Nifty Pharma sector has emerged as a pillar of stability, demonstrating notable resilience and delivering consistent returns over time. This defensive characteristic, particularly during periods of market volatility, makes it one of the more attractive sectors from a strategic investment standpoint.
Here’s how Nifty Pharma, an index which tracks the performance of the pharmaceutical sector in India, has performed over different time frames:
| TIme Frame | Returns |
| 1 Week | 0.81% |
| 1 Month | 4.23% |
| 3 Months | 6.71% |
| 6 Months | 4.5% |
| Year to Date | 2.4% |
| 1 Year | 6.4% |
| 3 Years | 83.7% |
| 6 Years | 71.98% |
Nifty Pharma shows steady short-term gains and moderate yearly returns, highlighting defensive stability. Strong 3-year performance reflects sector strength, though longer-term growth appears more measured, indicating consistent but not aggressive expansion.
Recent performance further reinforces this trend. As the Q4 earnings season gathers pace, several leading pharmaceutical companies have already reported steady and resilient results, while others are yet to announce their numbers.
Brokerage views remain mixed, while some firms see meaningful upside potential in select names, others have adopted a more neutral stance, reflecting a balanced outlook amid evolving market conditions.
Brokerage View on Pharma Stocks
Sun Pharma Share Price Target 2026
Motilal Oswal maintains a BUY on Sun Pharma with a target price of Rs 1,940, an upside potential of over 9 per cent from the current price level.
According to the brokerage, growth is supported by strong innovation momentum and consistent double-digit expansion in the domestic formulations segment.
It also flags that the US generics remain affected by regulatory issues. Estimates for FY26, FY27, and FY28 are largely unchanged, reflecting a stable outlook.
Nuvama upgrades Sun Pharma to BUY with a revised target price of Rs 1,875, an upside of 5.4 per cent. Strong Q3FY26 performance beat estimates, led by India growth through launches and volumes.
According to Nuvama, despite weak US generics, the outlook remains positive with GLP-1 opportunity and sustained domestic outperformance. Earnings estimates for FY26 and FY27 have been upgraded moderately.
Dr Reddy’s Laboratories Share Price Target 2026
Nomura maintains a BUY on Dr Reddy’s with a target price of Rs 1,600. The price target by the company reflects an upside of about 21 per cent.
Early generic entry and Canada approval may drive high initial realizations and market share gains. According to Normura, sustained growth in non-US markets could support re-rating and earnings visibility.
Granules India Share Price Target 2026
Motilal Oswal maintains a BUY on Granules India with a revised target price of Rs 820. The current target was hiked from its previous target of Rs 730, reflecting the rise potential of over 16 per cent.
The brokerage notes that margin expansion and operating leverage support earnings, prompting upgrades to FY26 and FY27 estimates amid an improving business mix.
Mankind Pharma Share Price Target 2026
Motilal Oswal maintains a BUY on Mankind Pharma with a target price of Rs 2,640. This reflects an upside of around 19 per cent.
Domestic formulations show healthy revival, driven by chronic therapies and improved execution. The brokerage highlights that the company’s strong revenue, EBITDA, and PAT growth outlook is supported by premiumization, scale benefits, and consistent traction from new launches and brand extensions.
| Stock Name | Brokerage | Target Price | Recommendation | Upside% |
| Sun Pharma | Motilal Oswal | 1,940 | BUY | 9% |
| Sun Pharma | Nuvama | 1,875 | BUY | ~5% |
| Dr Reddy’s Lab | Nomura | 1,600 | BUY | ~21% |
| Granules India | Motilal Oswal | 820 | BUY | ~16% |
| Mankind Pharma | Motilal Oswal | 2,640 | BUY | ~19% |
Bottom Line
Nifty Pharma remains a resilient, defensive sector with steady returns and earnings visibility. Brokerages stay bullish on key stocks, citing domestic growth, innovation, and margin expansion, though global challenges persist.
(Disclaimer: The above article is meant for informational purposes only, and should not be considered as any investment advice. ET NOW DIGITAL suggests its readers/audience to consult their financial advisors before making any money-related decisions.)
